Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Infanrix Hexa in Healthy Indian Infants
NCT01353703Phase 3Completed
- Sponsor
- GSK
- Start
- Apr 2012
- Primary completion
- Feb 2013
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pertussis filamentous haemagglutinin in diphtheria, Tetanus, pertussis and 3 more (2 arms), sponsored by GSK. Primary endpoints: Number of Seroprotected Subjects Against Diphtheria (D) and Tetanus (T) Antigens, Number of Seroprotected Subjects Against Hepatitis B (HBs) and 3 more. Started Apr 2012; status: completed.
02
Drugs
pertussis filamentous haemagglutinin
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)poliomyelitis
Beyond the preview
Go deeper on NCT01353703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01353703.